Document Detail


Activated protein C in toxic shock syndrome: a case report.
MedLine Citation:
PMID:  16573482     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
The mortality from septic shock remains high despite the availability of modern critical care facilities. In recent years, new agents have been tested to reduce morbidity and mortality in patients with severe sepsis. Among them, recombinant human activated protein C (rhAPC) has been reported to significantly reduce mortality and morbidity in patients with severe sepsis and one or more acute organ failures. We describe our experience with this drug in the early reversal of septic shock from toxic shock syndrome.
Authors:
K S Rachakonda
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine     Volume:  5     ISSN:  1441-2772     ISO Abbreviation:  Crit Care Resusc     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2006-03-31     Completed Date:  2006-04-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888170     Medline TA:  Crit Care Resusc     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  189-92     Citation Subset:  -    
Affiliation:
Department of Critical Care, Wollongong Hospital, Wollongong, New South Wales. rachakondas@iahs.nsw.gov.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections
Comment In:
Crit Care Resusc. 2003 Sep;5(3):165-7   [PMID:  16573475 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Iodine induced thyrotoxicosis following povidine-iodine dressings: a case report.
Next Document:  The Atkins Diet as a possible trigger for an ICU admission: a case report.